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ABSTRACT
Raf kinase inhibitory protein (RKIP), an endogenous inhibitor of the extracellular 
signal-regulated kinase (ERK) pathway, has been implicated as a suppressor 
of metastasis and a prognostic marker in cancers. However, how RKIP acts as a 
suppressor during metastasis is not fully understood. Here, we show that RKIP 
activity in cervical and stomach cancer is inversely correlated with endogenous 
levels of the Notch1 intracellular domain (NICD), which stimulates the epithelial to 
mesenchymal transition (EMT) and metastasis. The levels of RKIP were significantly 
decreased in tumor tissues compared to normal tissues, whereas NICD levels were 
increased. Overexpression of RKIP in several cell lines resulted in a dramatic decrease 
of NICD and subsequent inhibition of several mesenchymal markers, such as vimentin, 
N-cadherin, and Snail. In contrast, knockdown of RKIP exhibited opposite results 
both in vitro and in vivo using mouse models. Nevertheless, knockdown of Notch1 in 
cancer cells had no effect on the expression of RKIP, suggesting that RKIP is likely an 
upstream regulator of the Notch1 pathway. We also found that RKIP directly interacts 
with Notch1 but has no influence on the intracellular level of the γ-secretase complex 
that is necessary for Notch1 activation. These data suggest that RKIP plays a distinct 
role in activation of Notch1 during EMT and metastasis, providing a new target for 
cancer treatment.
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INTRODUCTION
Tumor metastasis is a multistep process that begins 
with the separation of cancer cells from the primary 
tumor followed by local invasion, intravasation into 
the bloodstream, extravasation, and final colonization 
at distant organs. Metastasis is the major cause of 
cancer-associated death and poor prognosis in humans. 
Each step of tumor metastasis requires specific cell-cell 
interactions and many different signaling pathways [1, 2]. 
Before the metastatic progression of a tumor begins, 
a cancer cell commits to a transition from an epithelial 
to a mesenchymal phenotype; this process is called the 
epithelial-mesenchymal transition (EMT). It allows cancer 
cells to be highly migratory during metastasis [3, 4]. 
The EMT process coincides with the simultaneous loss of 
epithelial markers, such as E-cadherin, and the acquisition 
of mesenchymal markers, such as N-cadherin and 
vimentin, by activating the transcriptional factors, Snail, 
Slug, Twist, and ZEB1/ZEB2 [5, 6]. 
Raf kinase inhibitory protein (RKIP) is an inhibitory 
protein in the Raf/mitogen-activated protein kinase 
(MAPK, or MEK)/extracellular signal-regulated kinase 
(ERK) pathway via a direct interaction with Raf-1 [7]. 
Thus, RKIP is a key signaling modulator in the MAPK 
pathway that controls cell fate under many cellular 
conditions [8]. RKIP also controls nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activity 
by suppressing the activity of inhibitors of κB kinase α 
and β (IKKα and IKKβ, respectively), NF-κB inducing 
kinase (NIK), and transforming growth factor-β-activated 
kinase 1 (TAK1) [9, 10]. In addition to these cellular 
functions, RKIP plays an important role in suppressing 
tumor progression and metastasis through coordination 
of these intracellular signals [11–13]; thus, it is known as 
a suppressor of metastasis and a good prognostic marker 
for identifying disease-free survival in cancer patients. 
According to many previous reports, RKIP is severely 
downregulated in many human primary cancers, such as 
the highly metastatic prostate [14–16], breast [17, 18], 
colon [19–21], ovarian [22], and cervical cancers [23, 24], 
and glioma [25]. These in vivo data complemented by 
in vitro studies suggest that RKIP could inhibit both the 
signaling pathway that governs EMT and the multistep 
process of metastasis from migration/invasion to homing. 
However, the detailed role of RKIP in the inhibitory 
mechanisms underlying these processes still remains to be 
discovered.
Activation of Notch signaling is a crucial step for 
tumor survival and progression [26, 27]. Indeed, the Notch 
pathway is aberrantly activated in many solid tumors, 
including cervical, head and neck, liver, lung, prostate, 
and breast cancer, and its activation is functionally 
associated with metastasis in these tumors [28]. Notch, 
a transmembrane receptor protein, is composed of 
four distinct family members (Notch1-4) in humans. 
In particular, ligand binding to Notch1 causes release of 
the Notch1 intracellular domain (NICD) via the proteolytic 
activity of the γ-secretase complex, which is composed 
of a catalytic subunit (Presenilin-1 or Presenilin-2) and 
accessory subunits (Presenilin enhancer 2 (PEN2), Aph1, 
and Nicastrin) [29, 30]. The NICD fragment subsequently 
translocates into the nucleus and forms a transcriptional 
complex with other factors, including mastermind-
like protein (Maml) and C-promoting binding factor 1 
(CBF1)/Suppressor of hairless/Lag-1 (CSL), resulting 
in the transcriptional activation of EMT-related genes, 
such as Slug or Snail [26, 27]. Therefore, activation of 
Notch1 (production of NICD) has been implicated in 
tumorigenesis, proliferation, and survival of several cancer 
cells. Moreover, NICD is associated with poor survival in 
patients with breast cancer and non-small cell lung cancer 
[31–35]. Some recent studies suggest that activation 
of Notch1 signaling promotes cancer metastasis by 
stimulating EMT via Snail- or Slug-mediated repression 
of E-cadherin in cancer cells [31, 33]. 
In this study, we aimed to understand the molecular 
mechanisms governing RKIP-dependent Notch1 activation 
in tumor progression using overexpression or knockdown 
of RKIP in cancer cells. We found that RKIP directly 
binds to Notch1 and prevents the proteolytic cleavage of 
Notch1 by γ-secretase. As a result, RKIP suppresses NICD 
production and inhibits NICD-mediated cell invasion and 
migration during metastasis. We also demonstrate that 
RKIP expression is inversely related to NICD activation in 
the cervical and stomach tissues of human cancer patients.
RESULTS
RKIP overexpression suppresses activation of 
Notch signaling in lung and cervical cancer cell 
lines 
Low expression levels of RKIP in tumor tissues 
are suggestive of poor prognoses in cancer patients, 
but the functional role of RKIP in cancer metastasis 
is still poorly defined. To investigate the functional 
relationship between RKIP and Notch signaling during 
the migration and invasion of cancer cells, we produced 
lung (H1299) or cervical (HeLa) cancer cell lines stably 
overexpressing FLAG-tagged RKIP proteins. Compared 
to endogenous levels of RKIP, both stable cell lines 
expressed higher levels of RKIP, but the levels of RKIP in 
H1299 lung cancer cells were higher than those observed 
in HeLa cervical cancer cells (Figure 1A, 1B). These 
RKIP-overexpressing cancer cells showed a similar 
pattern not only in cell proliferation and cell cycle 
regulation, but also in cell morphology compared to 
control cells (Supplementary Figure S1), suggesting 
that overexpression of FLAG-tagged RKIP does not 
influence cell growth and proliferation in these cancer cell 
lines. Interestingly, the levels of NICD, the intracellular 
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activated fragment of Notch1 (110kDa), were significantly 
decreased in RKIP-overexpressing H1299 cells compared 
to vector-only (pcDNA3.1) control cells, and similar 
results were observed in two FLAG-tagged RKIP 
clones (#2 and 4) (Figure 1A). Also, the NICD levels 
were similarly decreased when FLAG-tagged RKIP 
proteins were overexpressed in HeLa cells (Figure 1B). 
The NTM, a transmembrane fragment of Notch1 (120 kDa), 
was barely detected in both H1299 and HeLa cells 
overexpressing RKIP. Conversely, knockdown of RKIP 
in both H1299 and HeLa cells using a recombinant 
adenoviral RKIP shRNA-expressing vector (Ad-shRKIP) 
showed a significant increase of NICD production 
compared to control cells infected with a GFP-targeted 
recombinant adenoviral vector (Ad-shGFP) (Figure 1C). 
Nevertheless, knockdown of RKIP did not affect the 
mRNA levels of Notch1 in either H1299 or HeLa cells 
(Figure 1D), suggesting that RKIP-dependent NICD 
production is likely regulated post-translationally. 
Lastly, we also knocked down Notch expression using a 
Notch1 shRNA-expressing vector (pLK 0.1-shNotch1) in 
H1299 or HeLa cancer cells. Compared to control cells 
transfected with pLK 0.1-GFP shRNA, expression levels 
of RKIP were not affected in Notch1-knocking down 
cells (Figure 1E), suggesting that RKIP is an upstream 
component of Notch1 signaling in these cancer cells.
RKIP and NICD exhibit inverse expression 
patterns in cancerous human cervical and gastric 
tissues
As demonstrated above, overexpression of RKIP 
inhibited the production of NICD in cancer cells. To 
further assess how the expression of these two proteins 
is regulated in human cancers, we examined the relative 
expression of RKIP and NICD in cancer tissues derived 
from human patients. First, we compared expression levels 
in normal (three participants) and cancerous (eight patients) 
cervical tissues and found that RKIP levels were 
decreased in many cancerous cervical tissues compared 
to normal cervical tissues. In particular, RKIP levels 
were significantly lower in some patients (#4, 5, and 10), 
whereas the expression levels of NICD were highly 
elevated in these cancerous cervical tissues (Figure 2A). 
Thus, an inverse relationship exists between the expression 
levels of RKIP and NICD in human cancerous cervical 
tissue (Figure 2B). 
Second, we compared the expression of RKIP and 
NICD in paired stomach tissues (tumorous tissue and 
adjacent non-tumorous tissue) derived from nine patients 
with three different tumor-node-metastasis (TNM) stages 
(1–3). Compared to adjacent paired normal tissues, RKIP 
expression was highly elevated in the tumorous tissues 
of patients (except patient #1) with TNM stage 1, and 
NICD was barely detectable in both normal and tumorous 
tissues within the TNM stage 1 category (Figure 2C, 2D). 
However, RKIP was somewhat decreased in the tumorous 
tissues of patients with TNM stage 2 and 3 compared 
to matched non-tumorous tissues. Conversely, NICD 
was significantly increased in the tumor tissues found at 
these stages (Figure 2C, 2D). Lastly, we also examined 
the expression patterns of RKIP and NICD in highly 
metastatic Yonsei Cancer Center (YCC) cancer cells, 
which have been isolated and established from the ascite 
fluid or peripheral blood of Korean gastric cancer patients 
(obtained from the Yonsei Cancer Center in Korea). Some 
YCC clones (#3, 36, and 10) exhibited high expression of 
NICD but relatively low expression of RKIP compared 
to other YCC clones, which showed opposite expression 
patterns (Figure 2E, 2F). Overall, these data suggest that 
RKIP negatively regulates Notch signaling in human 
cervical and gastric cancers.
RKIP inhibits Notch1-mediated invasion and 
migration of cancer cells 
It has been proposed that the loss of RKIP in cancer 
cells leads to increased EMT. To investigate the possible 
role of RKIP in cancer, we investigated the invasive and 
migratory activities of H1299 lung cancer cells when 
RKIP was either overexpressed or knocked down in vitro. 
RKIP-overexpressing H1299 cells (FLAG-RKIP #2) 
significantly inhibited cell invasion in Transwell Matrigel 
assays compared to control H1299 cells (pcDNA) 
(Figure 3A, 3B). In contrast, ablation of RKIP in H1299 
cells highly stimulated in vitro cell invasion (Figure 3A, 3B). 
In addition to cell invasion, we observed similar results in 
wound-healing assays; overexpression of RKIP inhibited 
cell migration in a time-dependent manner, whereas RKIP 
knockdown greatly promoted migration of H1299 lung 
cancer cells (Figure 3C, 3D).
EMT is a prerequisite for cancer cells to become 
highly metastatic, and EMT occurs as the result of 
increased expression of EMT-related proteins, such as 
N-cadherin, Snail, and vimentin. As such, we tested 
whether overexpression or knockdown of RKIP could 
modulate the expression of these EMT-related proteins. As 
predicted, overexpression of FLAG-tagged RKIP in H1299 
cells (clones #2 and 4) significantly reduced expression of 
Snail, N-cadherin, and vimentin (Figure 3E, 3F), which 
likely coordinates with a decrease of NICD. In contrast, 
knockdown of RKIP (Ad-shRKIP) remarkably induced 
expression of Snail, N-cadherin, and vimentin compared 
to control H1299 cells (Ad-shGFP) (Figure 3G, 3H).
To further confirm whether RKIP acts as an inhibitor 
of Notch1 activation, we knocked down Notch1 in 
RKIP-overexpressing HeLa cells (clone #5) in which 
the NICD expression levels were inhibited up to 50% 
compared to control HeLa cells (0.55 ± 0.03, *p < 0.005, 
Figure 1B). Knockdown of NICD via Notch1 shRNA 
in HeLa cells overexpressing FLAG-tagged RKIP 
remarkably abolished RKIP-dependent suppression of cell 
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invasion compared to RKIP-overexpressing cells treated 
with control shRNA vector (Figure 4A, 4B). Furthermore, 
the decreased production of NICD mediated by Notch1 
shRNA in RKIP-overexpressing HeLa cells caused a 
significant decrease of EMT-related protein expression 
(Figure 4C, 4D). We also examined the migratory ability 
of HeLa cells in which both RKIP and Notch1 were 
simultaneously knocked down. Individually, ablation of 
RKIP stimulated cell migration in wound-healing assays, 
whereas knockdown of NICD inhibited cell migration 
(Figure 3C). However, cell migration in NICD- and 
RKIP-depleted cells was very similar to that observed 
during wound closure in non-treated cells; the previously 
observed increase in cell migration mediated by RKIP 
knockdown was abolished by the inhibition of Notch1 
activation (Figure 4E–4G). These data indicate that RKIP 
negatively regulates NICD-induced cell invasion and 
migration in tumorigenesis. 
Loss of RKIP promotes malignant progression of 
lung tumors in vivo 
To further elucidate the effects of RKIP knockdown 
on tumor metastasis in vivo, we used an orthotopic lung 
cancer model. We intravenously injected A549 lung cancer 
cells treated with Ad-shRKIP or Ad-shGFP into the tail 
vein of BALB/c nude mice and examined the metastatic 
lesions of the removed lungs after eight weeks. The nude 
Figure 1: RKIP negatively regulates Notch1 activation in lung and cervical cancer cell lines. (A, B) Stable cell lines 
expressing FLAG-tagged RKIP (FLAG-RKIP) or control vector (pcDNA) were established in H1299 (clones #2 and 4) and HeLa 
(clones #1, 3, and 5) cells. (Left) Total cell extracts (30 μg) were separated on 10% SDS gels and analyzed by western blot analysis using 
anti-RKIP or -Notch1 antibodies. β-actin was used as a loading control. (Right) The expression levels of RKIP or NICD in H1299 (A) and 
HeLa (B) cells were quantified and represented graphically. (C) In H1299 and HeLa cells, RKIP expression was either knocked down with 
adenoviral shRNA-RKIP (Ad-shRKIP) or unaffected using a control vector (Ad-GFP). The expression levels of RKIP and Notch1 (NICD) 
in total cell extracts were analyzed by western blot analysis using specific antibodies to each protein (top) and represented graphically 
(bottom). (D) Semi-quantitative RT-PCR analysis of Notch1 in RKIP- knocked down H1299 or HeLa cells. PCR products (295 bp for 
β-actin, 564 bp for RKIP, and 365 bp for Notch1) were separated on a 1.5% agarose gel (top) and quantified (bottom). (E) Expression 
of Notch1 in H1299 or HeLa cells was either abolished by transient transfection with Notch1 shRNA or unaffected in control vector 
transfections for 24 h. Each protein was analyzed by western blot analysis (top) and quantified (bottom). All data indicate the mean values 
± standard deviation (S.D.) of at least three independent experiments. *p < 0.05 or **p < 0.01 compared to normalized controls.
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mice transplanted with A549-Ad-shRKIP cells showed 
more severe tumor nodule formation in the lungs than 
mice treated with A549-Ad-shGFP cells (Figure 5A, 5C). 
Furthermore, we employed the four-stage grading system 
of H & E-stained lung tumor tissues to histologically 
monitor and quantify tumor development and progression 
(adopted from ref. 36). The criteria for each grade are 
as follows: Grade 1 tumors are atypical adenomatous 
hyperplasia (AAH) or small adenomas that have uniform 
nuclei (Figure 5Bb). Grade 2 tumors are larger adenomas 
that have solid tumor morphologies but slightly enlarged 
uniform nuclei with prominent nucleoli (Figure 5Bc, 5Bd). 
Grade 3 tumors have cells with enlarged pleomorphic 
nuclei and nuclear atypia (Figure 5Be, 5Bf). Grade 4 
tumors are invasive adenocarcinomas that have glandular/
acinar architectures (Figure 5Bg, 5Bh) and highly invasive 
stromal reactions (desmoplasia) to surrounding nests of 
tumor cells (Figure 5Bg, 5Bi). Based on this grading 
scheme, we confirmed that loss of RKIP (mediated by 
A549-Ad-shRKIP injections) caused the appearance of 
severe malignant tumors (average tumor grade: ~3) in the 
lung compared to control A549-Ad-shGFP-injected mice 
(average tumor grade: ~1.5) (Figure 5C, 5D). 
Next, we examined the expression profiles of RKIP 
and NICD in the lung tumors of these mice. Similar to 
our in vitro results, expression of NICD was significantly 
Figure 2: RKIP and NICD are inversely expressed in human cervical and stomach cancer tissues. (A, B) RKIP and 
NICD expression in human cervical cancer. (A) Proteins were extracted from normal (patients #1–3) and cancerous (patients #4–11) 
human cervical tissues. Total proteins (30 μg) were subjected to immunoblot analysis. (B) Expression of each protein (RKIP or NICD) 
was quantified by densitometric scans and represented graphically. *p < 0.05 compared to normalized controls. (C, D) RKIP and NICD 
expression in human stomach cancer. (C) Proteins were extracted from pairs of tumorous and adjacent non-tumorous tissues of nine 
human stomach cancer patients (patients #1–9) with three different TNM stages (stage 1: patients #1–4, stage 2: patients #5–7, and stage 3: 
patients #8–9). (D) RKIP and NICD expression in stomach cancer specimens (indicated by “C”) were quantified followed by normalization 
to the expression of each protein, respectively, in matched adjacent non-tumorous tissues (indicated by “N”) and represented graphically. 
*p < 0.05 compared to normalized controls. (E, F) Expression of RKIP and NICD in YCC gastric cancer clones (human advanced gastric 
cancer cell lines). (E) Nine YCC clones (#3, 6, 7, 9, 10, 16, 18, 21, and 36) were subjected to immunoblot analyses. (F) The expression 
levels of RKIP and NICD in YCC clones were quantified and represented graphically. β-actin was used as loading control. All data indicate 
the mean values ± S.D. of at least three independent experiments. *p < 0.05.
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elevated in the mice injected with Ad-shRKIP-expressing 
A549 lung cancer cells compared to control mice, and 
RKIP expression was relatively less significant because 
we analyzed these proteins on the total lung tissues that 
might have contained both normal and cancerous cells 
(Figure 5E, 5F). Furthermore, N-cadherin and vimentin, 
markers for EMT, were highly increased in the lung tissues 
of mice injected with Ad-shRKIP-expressing A549 cells, 
whereas the expression of E-cadherin was remarkably 
decreased in these mice (Figure 5E).
RKIP directly interacts with full-length Notch1 
but not NICD
Next, we investigated the physical interaction 
between RKIP and Notch1 in either H1299 or 
HeLa cells overexpressing FLAG-tagged RKIP using 
immunoprecipitation assays. In these cells, we readily 
detected the NICD fragment of Notch1 (110 kDa) but 
barely observed full-length (FL) Notch1 (300 kDa) with 
long exposures (Figure 6A), suggesting that very little 
FL-Notch1 was present. Using total proteins (1 mg) 
extracted from cell lysates, RKIP was immunoprecipitated 
with anti-FLAG antibodies (M2 agarose beads). 
We found that RKIP specifically bound to FL-Notch1 
(300 kDa) and did not associate with NICD fragments 
(Figure 6A, right panel).
Additionally, we investigated whether RKIP and 
Notch1 colocalize in cells using immunohistochemistry 
and cells expressing EGFP-RKIP proteins. These studies 
indicate that RKIP is likely colocalized with Notch1 in 
the cytoplasm (Figure 6B and 6C), suggesting that, by 
Figure 3: RKIP controls migration and invasion of cancer cells via downregulation of EMT proteins. (A) The Matrigel 
invasion chamber assay using RKIP-overexpressing or RKIP-knocking down H1299 cells. Cells that invaded the Transwell insert were 
stained with propidium iodide and photographed. (B) Cells were quantified by counting the cells in ten randomly selected fields under the 
microscope (10 × objective magnification). *p < 0.05. (C) The wound-healing assay using RKIP-overexpressing or RKIP-depleted H1299 
cells. Additional assay details described in “Materials and Methods.” Representative images (50 × magnification) indicate cell migration at 
given times. The wound edge at 0 h is indicated by white (dotted) lines. (D) Cell migration represented as relative wound closure (percentage 
of the average migratory distance of cells relative to the original wound edge). Data indicate the mean values ± S.D. of at least three 
independent experiments. *p < 0.05 compared to controls. Scale bar, 500 μm. (E–H) Regulation of EMT-related proteins by RKIP. (E, G) 
Expression of EMT proteins (N-cadherin, Snail, and vimentin) in RKIP-overexpressing or RKIP-knocking down H1299 cells examined 
via western blotting. β-actin was used as loading control. (F, H) The relative expression levels of the noted proteins, as determined by 
densitometric scans, represented graphically. Bars are the mean values ± S.D of three identical experiments. **p < 0.001.
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binding to FL-Notch1, RKIP could prevent the proteolytic 
cleavage of Notch1 mediated by γ-secretase to produce 
NICD, which would consequentially decrease the 
activation of Notch1 signaling. To test this possibility, 
we examined whether RKIP affects the expression of the 
γ-secretase complex enzymes, Presenilin-1 and -2, PEN2, 
and Nicastrin. However, we found that overexpression 
or knockdown of RKIP in H1299 cells had no effect 
on the expression of γ-secretase complex enzymes 
(Supplementary Figure S2). 
Notch1 activation in hypoxic environments is 
RKIP-dependent 
According to previous work, Notch1 signaling 
is highly activated under hypoxia [37, 38]. Here, we 
tested whether loss of RKIP is necessary for Notch1 
activation in hypoxic conditions that assessed by the 
level of Hif1α. As expected, Notch1 activation (as 
determined by NICD levels) was gradually increased in a 
time-dependent manner under hypoxia in normal 
H1299 cells, but it was significantly inhibited in cells 
overexpressing FLAG-tagged RKIP (Figure 7A, 7B). This 
RKIP-dependent Notch1 activation under hypoxia also 
affected the expression of EMT-related proteins; N-cadherin 
and vimentin were coordinately elevated with Notch1 
activation and conversely inhibited by overexpression of 
RKIP in hypoxic conditions (Figure 7A, 7B). In contrast, 
silencing RKIP expression in H1299 cells (Ad-shRKIP) 
stimulated Notch1 activation under hypoxia, leading to 
increases of N-cadherin and vimentin compared to control 
cells (Ad-shGFP) (Figure 7C, 7D). These data demonstrate 
that hypoxia-induced Notch1 activation is likely due to 
decreased expression of RKIP.
DISCUSSION
In the present study we showed that reduction of 
RKIP expression significantly increased production of an 
active form of Notch1, NICD, and subsequently promoted 
the metastatic ability of lung and cervical cancer cells. 
Figure 4: RKIP inhibits cell migration and invasion by directly downregulating Notch1 activity. (A, B) Cell invasion of 
NICD-depleted, RKIP-overexpressing HeLa cells (FLAG-RKIP #5) was assessed via the Matrigel invasion chamber assay. (A) Photographs 
of propidium iodide-stained cells that invaded the chamber. (B) Quantification of the number of migratory cells in ten randomly selected 
fields. **p < 0.001. (C, D) Effect of Notch1 ablation on expression of EMT proteins in HeLa cells overexpressing RKIP. (C) Notch1 
expression was knocked down by expressing the shNotch1 vector in RKIP-overexpressing HeLa cells (FLAG-RKIP #5), and total protein 
extracts (30 μg) were subjected to western blot analysis to examine the expression of the EMT markers, Snail and vimentin, in these cells. 
β-actin was used as loading control. (D) Relative expression levels of these proteins represented graphically. *p < 0.05. (E–G) Effect of 
Notch1 ablation on cell invasion in RKIP-overexpressing HeLa cells. Cell migration analysis of RKIP- and Notch1-knocked down H1299 
cells. The expression of both RKIP and Notch1 was knocked down by co-transfecting the shRKIP- and shNotch1-expressing vectors in 
H1299 cells. (E) Expression of RKIP and NICD in these cells was determined by western blot analysis. (F) Migratory behaviors of these 
cells were evaluated using the wound-healing assay. (G) Cell migration quantified as described in Figure 3. Data indicate the mean ± S.D 
of the wound edge closure (%) of monolayer cells compared to controls (0 h). *p < 0.05. Scale bar, 500 μm.
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Conversely, overexpression of RKIP inhibited cell invasion 
and migration of these cancer cells via downregulation 
of NICD. These data suggest that RKIP is an important 
negative regulator of Notch1 activation, which plays a 
pivotal role in cancer metastasis. Indeed, RKIP has been 
implicated as a suppressor of metastasis largely because 
it is significantly downregulated in many types of human 
metastatic tumors, such as prostate, breast, gastric, 
colorectal, lung, and cervical cancers. Loss of RKIP in 
prostate cancer cells shows metastatic phenotypes, and 
restoration of RKIP expression inhibits prostate cancer 
metastasis [14–16]. Additionally, the metastatic ability 
of breast cancer cells positively correlates with reduced 
levels of RKIP in human cancer cells, closely associating 
with poor prognosis in breast cancer patients [17, 18]. 
Survival rates and tumor progression in colorectal, 
ovarian, and cervical cancer patients are also related to 
the levels of RKIP in tumor tissues [19–24]. Despite 
many clinical implications between RKIP expression and 
cancer metastasis, the molecular mechanism regarding 
how downregulation of RKIP results in poor outcomes 
and malignant progression in human cancers is not clear.
Figure 5: Knockdown of RKIP promotes tumor metastasis in vivo in orthotopic lung cancer mouse models. (A) Images 
of metastatic lungs. Lungs were extracted from BALB/c nude mice injected with 1 × 106 cells (per mouse) of A549 only (A549-con), A549 
cells infected with Ad-GFP (A549-Ad-GFP), or A549 cells infected with Ad-shRKIP (A549-Ad-shRKIP) (n = 7 per group) and photographed 
to visually examine tumor nodules. Normal indicates non-treated mice. (B) Four-stage grading systems of lung adenocarcinoma. Based 
on tumor progression and histopathological phenotypes of H & E-stained tumor tissues, the lung cancer tissues were classified at four 
stage grades as follows: (a) normal lung tissue, (b) Grade 1 lesions of an atypical adenomatous hyperplasia (AAH) progressing to a 
small adenoma, (c) Grade 2 adenoma, (d) Grade 2 lesions form a solid tumor but have regular nuclei, (e) Grade 3 adenocarcinoma 
exhibiting enlarged pleomorphic nuclei and prominent nucleoli, (f) Grade 3 adenocarcinoma displaying mixed cellular phenotypes, (g) 
Grade 4 invasive adenocarcinoma, (h) Grade 4 adenocarcinoma with glandular/acinar architecture, and (i) Grade 4 adenocarcinoma with 
desmoplasia. Scale bar, 100 μm. (C) Representative H & E-stained lung tissues. Scale bar, 100 μm. (D) Distribution of tumor grades. Bars 
indicate the average values of four grades determined from tumor tissues for each mouse group. Data show mean ± S.D. *p < 0.05 (n = 7). 
(E, F) RKIP and NICD expression in lung adenocarcinoma tissues. (E) Total lysates of tumor tissues (four per group) were subjected to 
immunoblot analysis using the indicated antibodies. (F) Quantifications of RKIP and NICD expression levels represented graphically. Data 
indicate the mean values ± S.D. of three independent experiments. *p < 0.05; **p < 0.01.
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RKIP was initially identified as an inhibitor of the 
Raf/MEK/ERK pathway, which is necessary for growth 
and proliferation of cancer cells, via its direct interaction 
with Raf1 [7]. RKIP also stimulates glycogen synthase 
kinase 3β (GSK3β) signaling by blocking the inhibitory 
phosphorylation of GSK3β. Subsequently, the activated 
GSK3β inhibits EMT regulatory proteins, such as Snail 
or Slug, under a certain conditions [39, 40]. Therefore, 
RKIP-dependent suppression of the ERK or GSK3β 
pathways might be associated with the inhibitory role of 
RKIP in cancer metastasis. Additionally, in this report 
we suggest that RKIP directly interacts with Notch1 
and subsequently prevents the proteolytic cleavage of 
Notch1 by the γ-secretase complex, diminishing the 
release of NCID, the activated form of Notch1. Loss of 
RKIP expression in cancer cells highly stimulated cell 
invasion and migration and upregulated the expression 
of EMT-related proteins. Also, some other reports show 
that diminution of RKIP expression is directly associated 
with increase of cell growth and motility during cancer 
metastasis [41, 42]. Together these results suggest that 
RKIP-dependent activation of the Notch pathway in cancer 
cells may play a critical role in EMT and metastasis. 
According to other work, suppression of NICD 
proportionally prevents transcriptional activation of EMT-
related genes, such as snail or slug, leading to decreased 
migration and invasion of tumors [31–33]. Additionally, 
it has been reported that Notch signaling is frequently 
upregulated in human malignant tumor tissues, including 
cervical, lung, colon, gastric, head and neck, prostate, and 
Figure 6: RKIP directly interacts with full-length Notch1. (A) The left panel indicates the input of RKIP and Notch1 in 
FLAG-tagged, RKIP-overexpressing cells. Total cell lysates (1 mg) of FLAG-tagged, RKIP-overexpressing H1299 or HeLa cells and control 
cells expressing pcDNA were immunoprecipitated (IP) using anti-FLAG antibodies (M2 beads), and the bound Notch1 proteins were detected 
by immunoblotting (IB) with anti-Notch1 antibodies. (B) Co-localization of RKIP and Notch1 using immunohistochemistry. FLAG-tagged, 
RKIP-overexpressing H1299 cells were fixed, stained with both FITC-conjugated anti-RKIP antibodies and Cy5-conjugated anti-Notch1 
antibodies, and visualized under the fluorescent microscope. The nuclei were stained with H33342 dye. White dotted boxed regions correspond 
to the higher magnification images below. (C) Co-localization of EGFP-RKIP and Notch1. EGFP-tagged, RKIP-overexpressing H1299 cells 
were fixed, stained with both GFP and Cy5-conjugated anti-Notch1 antibodies, and visualized under the fluorescent microscope.
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pancreatic cancers [26–30]. In particular, Notch signaling 
has been suggested to contribute to the progression of 
non-small cell lung cancer [34, 35]. In this study, 
activation of Notch1 (NICD production) in lung and 
cervical cancer cell lines also promotes tumor invasion/
migration and upregulation of EMT-related proteins. 
Moreover, Notch-dependent metastasis can be stimulated 
by the reduction of RKIP in vitro in cancer cells. 
Furthermore, the highly increased expression of NICD 
in human cervical cancer tissues and tumorous tissues of 
stomach cancer patients with TNM stage 2 is inversely 
associated with low expression of RKIP in human tumor 
tissues. However, the role of Notch signaling in cervical 
cancer is seemingly controversial. Although many 
cervical tumors are consistently characterized by features 
associated with misregulation of Jagged1-induced Notch 
signaling, expression of Notch1 is remarkably reduced or 
absent in some invasive cervical cancer tissues [43–45]. 
Overall, Notch signaling plays a critical role in tumor 
progression and metastasis, and its activation is closely 
related to RKIP levels in human tumor tissues. 
We suggest that RKIP serves as a physiological 
inhibitor of Notch1 signaling. This raises the question of 
how RKIP regulates the levels of NICD in tumor cells. In 
the present study, knockdown of RKIP caused a significant 
decrease of NICD but no change in the levels of Notch1 
mRNA, suggesting that NICD activation is likely regulated 
post-translationally in an RKIP-dependent manner. Upon 
activation of Notch signaling, Notch1 is cleaved in a 
stepwise manner mediated by the proteolytic actions of 
the γ-secretase complex, leading to the subsequent release 
of NICD [30]. Therefore, inhibition of γ-secretase would 
prevent Notch1 activation, resulting in suppression of the 
Notch signaling pathway. Interestingly, RKIP can directly 
interact with full-length Notch1 but not NICD. These 
data suggest that RKIP prevents activation of Notch1 by 
directly binding to the Notch1 intracellular/transmembrane 
domain, consequently inhibiting the proteolytic activity of 
γ-secretase (Figure 7E). 
Hypoxia in tumors is closely associated with 
the potentiation of metastasis via the activation of 
Notch signaling. According to previous reports, 
Notch signaling directly modulates the expression of 
EMT-related proteins by upregulating the expression 
of Snail and downregulating E-cadherin expression in 
hypoxic conditions, which stimulates hypoxia-induced 
Figure 7: RKIP inhibits NICD-induced EMT in hypoxia. (A–D) RKIP-overexpressing H1299 cells (A, B) or RKIP-depleted 
H1299 cells (C, D) were incubated under hypoxic conditions (1% O2) for the indicated times. (A, C) Total cell extracts (30 μg) were 
subjected to western blot analysis to examine the expression of each noted protein at the indicated times. (B, D) Expression of each 
protein was quantified and represented graphically. Data indicates the mean values ± S.D. of three independent experiments. *p < 0.05. 
(E) Schematic illustration of RKIP-mediated regulation of Notch1. human Notch receptor 1 (hNotch1) contains two large regions: NEC 
(Notch extracellular subunits) and NICD (Notch intracellular domain). NICD consists of many motifs, including epidermal growth 
factor-like repeats (EGFR), Lin12 Notch repeats (LNR), a RAM23 domain (RAM), and Ankyrin repeats (ANK). NICD released by 
γ-secretase is translocated into the nucleus to activate the translation of EMT-related genes, subsequently promoting cell invasion and 
metastasis. When RKIP is overexpressed, tumor metastasis is blocked by RKIP-mediated inhibition of Notch1 activation.
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tumor cell migration and invasion [37, 38, 46, 47]. 
Furthermore, Notch signaling stabilizes Snail by stimulating 
the expression of lysine oxidase (LOX) via recruitment of 
hypoxia-inducible factor 1α (HIF1α) to the LOX promoter 
[37]. Therefore, tumor hypoxia appears to be strongly 
associated with tumor propagation, malignant progression, 
and resistance to therapy. Consistent with these reports, 
we found that hypoxia potentiated Notch signaling in 
H1299 lung cancer cells. However, this hypoxia-induced 
Notch1 activation was significantly inhibited by RKIP 
overexpression and stimulated by knockdown of RKIP 
(Figure 7). Recently, Morecroft et al. (2011) suggested 
that the lack of RKIP results in exaggerated pulmonary 
arterial hypertension (PAH) in hypoxia [48]. They also 
indicated that hypoxia increases activation of the Raf1/
ERK pathway by promoting dissociation of RKIP 
from Raf1. These data support the notion that hypoxia-
induced EMT is functionally linked to RKIP expression, 
which subsequently modulates Notch signaling during 
metastasis.  
In addition to its role as an inhibitor of Notch 
signaling, demonstrated by the present study, RKIP 
has been implicated as a suppressor of metastasis via 
control of the NF-κB/Snail/YY1/RKIP circuitry [49–51]. 
Hyperactivation of NF-κB in cancer cells transcriptionally 
activates the expression of Snail and Yin Yang 1 (YY1), 
and YY1 can also upregulate Snail. The high level of Snail 
in tumors consequently suppresses the expression of anti-
metastatic RKIP. Additionally, NF-kB inhibits RKIP and 
vice versa. As a result, cancer cells become resistant to 
chemotherapeutic drugs, leading to high incidences of 
metastasis and poor outcomes. Furthermore, although 
molecular links between Notch1 and NF-κB during 
tumor progression and metastasis have been suggested 
by the previous work [46, 52], a mechanism of disrupting 
or directly regulating Notch1 signaling from within the 
NF-kB/Snail/YY1/RKIP loop was unclear. Our findings 
indicate that RKIP suppresses activation of Notch1 
to inhibit EMT and metastasis, thereby identifying a 
mechanistic regulatory link between RKIP and Notch 
signaling. 
In conclusion, RKIP, a good marker for cancer 
prognoses, directly controls the activation of Notch 
signaling at the post-translational level. Presumably, it 
blocks the proteolytic activation of Notch1 by γ-secretase, 
thereby suppressing the production of active NICD. 
Cancer cells lacking of RKIP expression exhibit more 
aggressive phenotypes with activation of NICD-induced 
EMT protein expression. Our findings additionally 
suggest that the RKIP–NICD signaling axis is not only 
critical for controlling cancer progression and metastasis, 
at least in lung, cervical, and gastric cancers, but also for 
regulating the NF-kB/Snail/YY1/RKIP loop. Therefore, 
small molecules that mimic the RKIP-dependent 
inhibition of γ-secretase would be good candidates for 
the treatment of Notch-induced tumor progression. 
Furthermore, the identification of such small molecules 
would provide valuable alternatives to the ineffective 
γ-secretase inhibitors that fail to pass clinical trials due to 
dose-limiting toxicities or developments of resistance.
MATERIALS AND METHODS
Human tissue samples
Tumorous and adjacent non-tumorous tissues 
were collected immediately after surgical resection from 
cervical or gastric cancer patients who were diagnosed 
with pathologic tumor-node-metastasis (TNM) disease 
(stage 1–3) at the Hospital of Gyeongsang National 
University. Tissue specimens were snap-frozen and stored 
at −80°C. Serial tissue samples were used for protein 
extraction, stained with hematoxylin and eosin (H & E), 
and reviewed by pathologists to confirm the diagnoses. 
This study has been approved by the Institutional Review 
Board of the Hospital of Gyeongsang National University 
(IRB #2014–10–024–001, #2012–09–014).
Cell lines and cell culture
H1299, HeLa, and A549 cell lines were obtained 
from the American Type Culture Collection. Yonsei 
Cancer Center (YCC) cell lines were established from 
the ascites or peripheral blood of patients with advanced 
gastric cancer by the Cancer Metastasis Research Center 
at Younsei University College of Medicine (Seoul, Korea). 
H1299 and A549 cells were maintained in Roswell 
Park Memorial Institute (RPMI)-1640 medium (Gibco) 
containing 10% fetal bovine serum (FBS; Gibco). HeLa 
cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Gibco) containing 10% FBS. YCC cell lines 
were maintained in Minimum Essential Medium (MEM; 
Gibco) supplemented with 1 × non-essential amino acids 
solution (Gibco) and 10% FBS. All cells were grown at 
37°C in a humidified atmosphere of 95% air and 5% CO2. 
For hypoxic treatment, cells were placed in a modulator 
incubator (Thermo Electron Co.) in an atmosphere 
consisting of 94% N2, 5% CO2, and 1% O2 for a given time.
Plasmid constructs, transfection, stable cell lines, 
and adenoviral vectors
The pcDNA3.1-FLAG-hRKIP plasmid was kindly 
provided by Dr. Walter Kolch (University of Glasgow, 
Glasgow, United Kingdom). The shRNA plasmid against 
human Notch1 (NM _017617) was purchased from 
Sigma-Aldrich. H1299 and HeLa cells were transfected 
with plasmids using Lipofectamine2000 (Invitrogen) 
following the manufacturer’s instructions and stably 
selected in culture medium containing 500 μg/ml G418 
(Invitrogen) for two weeks. To generate the RKIP shRNA 
adenoviral expression vector, oligonucleotide sequences 
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(5′-GGATCCCAAATACAGAGAATG-3′) were cloned using 
the BLOCK-iT™ Adenoviral RNAi kit (Invitrogen) following 
the manufacturer’s instructions. GFP target sequences were 
used as negative controls. pAd/BLOCK-iT™–DEST-RKIP 
(Ad-shRKIP) and pAd/BLOCK-iT™–DEST-GFP (Ad-GFP) 
plasmids were transfected into 293A cells using Lipofectamine 
2000 to obtain viral particles. After 10 days, the viral particles 
were harvested from the cells and media. The concentrated 
viruses were used to infect cells. For adenoviral infection, cells 
were plated in 6-well plates at a density of 1 × 105 cells/mL, 
infected with adenoviruses at a multiplicity of infection (MOI) 
of 100, and incubated for 48 h at 37°C.
Cell invasion assay
A Transwell insert (3422; Corning) with an 8-μm 
pore size was used to carry out the two-chamber migration 
assay. The upper surface of the Transwell insert was coated 
with Matrigel (BD Biosciences; 50 mg/filter), and cells 
were seeded in a serum free medium. Serum-containing 
medium (10% FBS) was used in the lower chamber as a 
chemoattractant. After 20 h, cells that had invaded through 
the bottom surface of the insert were fixed, stained with 
propidium iodide (Invitrogen), and photographed. These 
cells were also quantified by counting the number of 
cells in 10 randomly selected viewing fields under the 
microscope (10 × magnification).
Wound-healing (scratch) assay
Cells were grown to confluence in a 60-mm 
dish, and a “wounding” line was scratched into the 
cell monolayer with a sterile 1000-μL pipette tip in 
three separate places. The width of the wound area was 
photographed and measured under the inverted phase 
contrast microscope (Nikon, 50 × magnification) to assess 
cell migration at 0, 12, and 36 h after scratching.
RT-PCR
Total cellular RNAs were purified with the TRIZOLR 
reagent (Life Technology) using the manufacturer’s 
instructions. For RT-PCR experiments, the total RNA 
(1 μg) was subjected to reverse transcription to produce 
cDNA. A two-step cycling protocol was used to anneal 
a pair of primers and elongate DNA synthesis at 55°C. 
The following forward and reverse primers, respectively, 
were used: β-actin, 5′-TCA CCC ACA CTG TGC CCA 
TCT ACG A-3′ and 5′-CAG CGG AAC CGC TCA TTG 
CCA ATG G-3′; RKIP, 5′-ATG CCG GTG GAC CTC 
AGC AAG T-3′ and 5′-CGA GCA GCT GTC TGG GAA 
GTA G-3′; Notch1, 5′-GGC CAC CTG GGC CGG AGC 
TTC-3′ and 5′-GCG ATC TGG GAC TGC ATG CTG-3′. 
Each sample was amplified in triplicate. Amplification of 
β-actin cDNA was used as the endogenous normalization 
standard. The β-actin, RKIP, and Notch1 PCR products 
were 295, 564, and 365 bp, respectively. PCR products 
were analyzed on a 1.5% agarose gel and photographed 
with the Polaroid Type 667 instant film.
Western blot analysis
Total proteins were extracted from cell lines and 
tissues with radioimmunoprecipitation assay (RIPA) lysis 
buffer supplemented with a protease inhibitor cocktail 
(Calbiochem). Protein concentration was determined with 
the Pierce protein assay kit (Pierce). Total protein lysates 
(30 μg) were separated by SDS-PAGE, and the target 
proteins were specifically detected by western blotting 
with antibodies against RKIP (Santa Cruz Biotechnology, 
sc-28837), Notch1 (Cell Signaling Technology, 3608), 
cleaved Notch1 (NICD; Cell Signaling Technology, 4147), 
N-cadherin (Cell Signaling Technology, 4061), Snail 
(Santa Cruz Biotechnology, sc-28199), vimentin (Santa 
Cruz Biotechnology, sc-6601), Presenilin-1 (Cell 
Signaling Technology, 5643), Presenilin-2 (Cell Signaling 
Technology, 9979), PEN2 (Cell Signaling Technology, 
8598), Nicastrin (Cell Signaling Technology, 9447), and 
β-actin (Sigma-Aldrich, A5441). Proteins were visualized 
with the Enhanced Chemiluminescence Detection Reagent 
(Pierce) and quantified using the Sigma-Gel software. 
Each data was corrected by b-actin and normalized to the 
control value.
Tumor metastasis assay in vivo 
All procedures were conducted in accordance 
with the National Institutes of Health (NIH) guidelines 
and approved by the Institutional Animal Care and 
Use Committee (IACUC) of the Gyeongsang National 
University (GNU-141119-M0057). For in vivo tumor 
metastasis studies using an orthotopic lung cancer model, 
BALB/c nude mice (males, six weeks old) were randomly 
divided into three groups (n = 7). A549 cells were infected 
with recombinant adenovirus expressing RKIP shRNA 
(A549-Ad-shRKIP) or GFP (A549-Ad-GFP) for 48 h. 
A549 (A549-con), A549-Ad-shRKIP, or A549-Ad-GFP 
cells (1 × 106 cells per animal) were suspended in 0.1 mL 
of sterile phosphate-buffered saline (PBS) and injected 
into the tail vein of BALB/c nude mice. After six weeks, 
the mice were sacrificed, and the lungs were extracted. 
The right lung was directly frozen in liquid nitrogen and 
stored at −80°C for western blotting, and the left lung was 
fixed in 10% formalin and embedded in paraffin. Five-
micrometer sections were cut and stained with H & E.
MTT assay
Cell viability of RKIP-overexpressing H1299 
or HeLa cells was determined by the methylthiazol 
tetrazolium (MTT) assay. Cells (2,000 cells per well) 
were seeded in 96-well plates. After 24, 48, 72, and 96 h, 
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20 μL of MTT (5 mg/ml) was added to each well. Cells were 
incubated at 37°C for an additional 4 h. The reaction was 
terminated by lysing cells with 200 μL DMSO for 5 min. 
Absorbance was measured at 550 nm in a microplate 
reader (Hidex). Each experiment was performed in 
triplicate and repeated three times.
Flow cytometeric cell cycle analysis
Cells were collected, fixed with ice-cold 70% 
ethanol for 30 min, and stained with propidium iodide 
(PI) solution (20 μg/mL of PI and 250 μg/mL of RNase in 
a solution of 0.1% Triton X-100 in PBS) for 30 min. Cell 
cycle was analyzed using the EPICS-XL flow cytometer 
(Beckman Coulter).
Statistical analysis
Each experiment was conducted independently at 
least three times, and values were expressed as the mean 
value ± standard deviation (S.D.). The difference between 
two groups was assessed by a two-tailed student’s t-test. 
Analysis of Variance (ANOVA) statistics were used to 
compare the means of three groups or more, and these 
values were verified by the Nonparametric Mann-Whitney 
U test. Values of p < 0.05 were considered significant.
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